Steven C Gilman - Net Worth and Insider Trading

Steven C Gilman Net Worth

The estimated net worth of Steven C Gilman is at least $666,254 dollars as of 2023-03-22. Steven C Gilman is the Director of Momenta Pharmaceuticals Inc and owns about 7,796 shares of Momenta Pharmaceuticals Inc (MNTA) stock worth over $409,134. Steven C Gilman is the Director of Vericel Corp and owns about 5,200 shares of Vericel Corp (VCEL) stock worth over $158,080. Steven C Gilman is also the Director of Keryx Biopharmaceuticals Inc and owns about 17,333 shares of Keryx Biopharmaceuticals Inc (KERX) stock worth over $58,239. Besides these, Steven C Gilman also holds Akebia Therapeutics Inc (AKBA) , SCYNEXIS Inc (SCYX) , ContraFect Corp (CFRX) . Details can be seen in Steven C Gilman's Latest Holdings Summary section.

Transaction Summary of Steven C Gilman

Steven C Gilman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Steven C Gilman owns 6 companies in total, including Momenta Pharmaceuticals Inc (MNTA) , SCYNEXIS Inc (SCYX) , and Akebia Therapeutics Inc (AKBA) among others .

Click here to see the complete history of Steven C Gilman’s form 4 insider trades.

Insider Ownership Summary of Steven C Gilman

Ticker	Comapny	Transaction Date	Type of Owner
MNTA	Momenta Pharmaceuticals Inc	2020-10-01	director
SCYX	SCYNEXIS Inc	2015-02-25	director
AKBA	Akebia Therapeutics Inc	2018-12-12	director
CFRX	ContraFect Corp	2015-05-18	director
VCEL	Vericel Corp	2015-03-20	director
KERX	Keryx Biopharmaceuticals Inc	2018-12-12	director

Steven C Gilman Latest Holdings Summary

Steven C Gilman currently owns a total of 6 stocks. Among these stocks, Steven C Gilman owns 7,796 shares of Momenta Pharmaceuticals Inc (MNTA) as of August 5, 2020, with a value of $409,134 and a weighting of 61.41%. Steven C Gilman owns 5,200 shares of Vericel Corp (VCEL) as of April 29, 2022, with a value of $158,080 and a weighting of 23.73%. Steven C Gilman also owns 17,333 shares of Keryx Biopharmaceuticals Inc (KERX) as of June 11, 2018, with a value of $58,239 and a weighting of 8.74%. The other 3 stocks Akebia Therapeutics Inc (AKBA) , SCYNEXIS Inc (SCYX) , ContraFect Corp (CFRX) have a combined weighting of 6.12% among all his current holdings.

Latest Holdings of Steven C Gilman

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MNTA	Momenta Pharmaceuticals Inc	2020-08-05	7,796	52.48	409,134
VCEL	Vericel Corp	2022-04-29	5,200	30.40	158,080
KERX	Keryx Biopharmaceuticals Inc	2018-06-11	17,333	3.36	58,239
AKBA	Akebia Therapeutics Inc	2022-06-03	43,430	0.70	30,401
SCYX	SCYNEXIS Inc	2020-12-21	4,000	1.56	6,240
CFRX	ContraFect Corp	2017-07-25	2,080	2.00	4,160

Holding Weightings of Steven C Gilman

Steven C Gilman Form 4 Trading Tracker

According to the SEC Form 4 filings, Steven C Gilman has made a total of 4 transactions in Momenta Pharmaceuticals Inc (MNTA) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Momenta Pharmaceuticals Inc is the sale of 13,000 shares on August 5, 2020, which brought Steven C Gilman around $425,750.

According to the SEC Form 4 filings, Steven C Gilman has made a total of 8 transactions in Vericel Corp (VCEL) over the past 5 years, including 0 buys and 8 sells. The most-recent trade in Vericel Corp is the sale of 900 shares on April 29, 2022, which brought Steven C Gilman around $27,846.

According to the SEC Form 4 filings, Steven C Gilman has made a total of 2 transactions in Keryx Biopharmaceuticals Inc (KERX) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Keryx Biopharmaceuticals Inc is the sale of 1,334 shares on June 11, 2018, which brought Steven C Gilman around $6,830.

More details on Steven C Gilman's insider transactions can be found in the Insider Trading History of Steven C Gilman table.

Insider Trading History of Steven C Gilman

Ticker
AKBA
VCEL
VCEL
VCEL
AKBA
SCYX
MNTA
MNTA
MNTA
AKBA
AKBA
VCEL
VCEL
VCEL
VCEL
MNTA
KERX
KERX
CFRX

Ticker	Company	Date	Buy/Sell	Insider Trading Shares	Shares Change	Price	Cost	Final Share	Current Price	Price Change Since Insider Trade (%)	Filing Date
AKBA	Akebia Therapeutics Inc	2022-06-03	Sell	4,567.00	-9.52%	$0.36	$1,644.12	43,430.00	$0.70	94.44%	2022-06-07
VCEL	Vericel Corp	2021-11-29	Sell	5,000.00	-58.82%	$39.17	$195,850.00	3,500.00	$30.40	-22.39%	-
VCEL	Vericel Corp	2021-10-27	Sell	5,000.00	-58.82%	$50.57	$252,850.00	3,500.00	$30.40	-39.89%	-
VCEL	Vericel Corp	2021-09-30	Sell	5,000.00	-58.82%	$48.85	$244,250.00	3,500.00	$30.40	-37.77%	-
AKBA	Akebia Therapeutics Inc	2021-06-07	Sell	4,567.00	-8.69%	$3.32	$15,162.40	47,997.00	$0.70	-78.92%	-
SCYX	SCYNEXIS Inc	2020-12-21	Buy	4,000.00	100.00%	$6.25	$25,000.00	4,000.00	$1.56	-75.04%	-
MNTA	Momenta Pharmaceuticals Inc	2020-08-05	Sell	13,000.00	-62.51%	$32.75	$425,750.00	7,796.00	$52.48	60.24%	-
MNTA	Momenta Pharmaceuticals Inc	2020-07-29	Sell	10,000.00	-56.19%	$29.70	$297,000.00	7,796.00	$52.48	76.70%	-
MNTA	Momenta Pharmaceuticals Inc	2020-07-22	Sell	10,000.00	-56.19%	$33.23	$332,300.00	7,796.00	$52.48	57.93%	-
AKBA	Akebia Therapeutics Inc	2020-06-08	Sell	4,567.00	-10.52%	$12.08	$55,169.40	38,864.00	$0.70	-94.21%	-
AKBA	Akebia Therapeutics Inc	2019-11-20	Buy	5,800.00	24.24%	$3.43	$19,894.00	29,731.00	$0.70	-79.59%	-
VCEL	Vericel Corp	2019-05-01	Sell	7,500.00	-100.00%	$16.81	$126,075.00	0	$30.40	80.84%	-
VCEL	Vericel Corp	2019-02-28	Sell	7,500.00	-100.00%	$18.02	$135,150.00	0	$30.40	68.70%	-
VCEL	Vericel Corp	2018-12-03	Sell	8,500.00	-100.00%	$17.75	$150,875.00	0	$30.40	71.27%	-
VCEL	Vericel Corp	2018-09-04	Sell	9,000.00	-100.00%	$12.03	$108,270.00	0	$30.40	152.70%	-
MNTA	Momenta Pharmaceuticals Inc	2018-06-22	Sell	2,294.00	-40.01%	$21.50	$49,321.00	3,440.00	$52.48	144.09%	-
KERX	Keryx Biopharmaceuticals Inc	2018-06-11	Sell	1,334.00	-7.15%	$5.12	$6,830.08	17,333.00	$3.36	-34.38%	-
KERX	Keryx Biopharmaceuticals Inc	2018-05-29	Sell	1,333.00	-6.67%	$5.22	$6,958.26	18,667.00	$3.36	-35.63%	-
CFRX	ContraFect Corp	2016-07-27	Buy	2,000.00	11.11%	$24.80	$49,600.00	2,000.00	$2.00	-91.94%	-

Total 19

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Steven C Gilman Trading Performance

GuruFocus tracks the stock performance after each of Steven C Gilman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Steven C Gilman is 54.51%. GuruFocus also compares Steven C Gilman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Steven C Gilman within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Steven C Gilman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Steven C Gilman

Average Relative Return

9.6%

Average relative return per transaction

Outperforming Transactions

50%

2 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Relative Return(%)	23.22	54.51	67.13	9.6	-26.35	-40.49
Relative Return to S&P 500(%)	21.56	50.49	59.51	-7.74	-38.74	-50.27

Steven C Gilman Ownership Network

Ownership Network List of Steven C Gilman

No Data

Ownership Network Relation of Steven C Gilman

Steven C Gilman Owned Company Details

What does Momenta Pharmaceuticals Inc do?

Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.

Who are the key executives at Momenta Pharmaceuticals Inc?

Steven C Gilman is the director of Momenta Pharmaceuticals Inc. Other key executives at Momenta Pharmaceuticals Inc include Chief Legal Officer Alejandra Carvajal , Chief Scientific Officer Anthony M. Manning , and SVP & Chief Medical Officer Santiago Arroyo .

Momenta Pharmaceuticals Inc (MNTA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Momenta Pharmaceuticals Inc (MNTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Momenta Pharmaceuticals Inc (MNTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Momenta Pharmaceuticals Inc (MNTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:MNTA Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does SCYNEXIS Inc do?

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Who are the key executives at SCYNEXIS Inc?

Steven C Gilman is the director of SCYNEXIS Inc. Other key executives at SCYNEXIS Inc include Chief Financial Officer Ivor Macleod , Interim CFO Lawrence R Hoffman , and Chief Commercial Officer Christine Coyne .

SCYNEXIS Inc (SCYX) Insider Trades Summary

Over the past 18 months, Steven C Gilman made no insider transaction in SCYNEXIS Inc (SCYX). Other recent insider transactions involving SCYNEXIS Inc (SCYX) include a net purchase of 75,000 shares made by Marco Taglietti , and a net purchase of 3,500 shares made by Scott Sukenick .

In summary, during the past 3 months, insiders sold 0 shares of SCYNEXIS Inc (SCYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SCYNEXIS Inc (SCYX) were sold and 78,500 shares were bought by its insiders, resulting in a net purchase of 78,500 shares.

SCYNEXIS Inc (SCYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:SCYX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Akebia Therapeutics Inc do?

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Who are the key executives at Akebia Therapeutics Inc?

Steven C Gilman is the director of Akebia Therapeutics Inc. Other key executives at Akebia Therapeutics Inc include SVP & Chief Accounting Officer Violetta Cotreau , SVP & CFO and Treasurer David A Spellman , and SVP & Chief Medical Officer Steven Keith Burke .

Akebia Therapeutics Inc (AKBA) Insider Trades Summary

Over the past 18 months, Steven C Gilman made 1 insider transaction in Akebia Therapeutics Inc (AKBA) with a net sale of 4,567. Other recent insider transactions involving Akebia Therapeutics Inc (AKBA) include a net sale of 22,809 shares made by Steven Keith Burke , a net sale of 130,500 shares made by John P. Butler , and a net sale of 30,502 shares made by Michel Dahan .

In summary, during the past 3 months, insiders sold 217,124 shares of Akebia Therapeutics Inc (AKBA) in total and bought 0 shares, with a net sale of 217,124 shares. During the past 18 months, 228,671 shares of Akebia Therapeutics Inc (AKBA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 228,671 shares.

Akebia Therapeutics Inc (AKBA)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:AKBA Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does ContraFect Corp do?

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Who are the key executives at ContraFect Corp?

Steven C Gilman is the director of ContraFect Corp. Other key executives at ContraFect Corp include 10 percent owner Fosun Industrial Co., Ltd , 10 percent owner Shanghai Fosun Pharmaceutical (group) Co., Ltd. , and Chief Medical Officer Cara M Cassino .

ContraFect Corp (CFRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ContraFect Corp (CFRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ContraFect Corp (CFRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ContraFect Corp (CFRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:CFRX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Vericel Corp do?

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Who are the key executives at Vericel Corp?

Steven C Gilman is the director of Vericel Corp. Other key executives at Vericel Corp include Chief Operating Officer Michael Halpin , Chief Medical Officer Jonathan Mark Hopper , and Chief Financial Officer Mara Joseph Anthony Jr .

Vericel Corp (VCEL) Insider Trades Summary

Over the past 18 months, Steven C Gilman made 4 insider transaction in Vericel Corp (VCEL) with a net sale of 15,900. Other recent insider transactions involving Vericel Corp (VCEL) include a net sale of 39,938 shares made by Dominick Colangelo , a net sale of 15,881 shares made by Jonathan Mark Hopper , and a net sale of 10,000 shares made by Michael Halpin .

In summary, during the past 3 months, insiders sold 39,938 shares of Vericel Corp (VCEL) in total and bought 0 shares, with a net sale of 39,938 shares. During the past 18 months, 82,050 shares of Vericel Corp (VCEL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 82,050 shares.

Vericel Corp (VCEL)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:VCEL Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

What does Keryx Biopharmaceuticals Inc do?

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Who are the key executives at Keryx Biopharmaceuticals Inc?

Steven C Gilman is the director of Keryx Biopharmaceuticals Inc. Other key executives at Keryx Biopharmaceuticals Inc include director & Interim CEO Jodie Pope Morrison , Chief Financial Officer Scott A Holmes , and 10 percent owner Baupost Group Gp, L.l.c. .

Keryx Biopharmaceuticals Inc (KERX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Keryx Biopharmaceuticals Inc (KERX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Keryx Biopharmaceuticals Inc (KERX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Keryx Biopharmaceuticals Inc (KERX)'s detailed insider trading history can be found in Insider Trading Tracker table.

NAS:KERX Insider Transactions

20/Page

Total 0

Insider	Position	Date	Buy/Sell	Shares	Shares Owned	Trade Price($)	Trade Percentage(%)	Cost($1000)	Price change since trade(%)	Share ownership details	Filing Date

20/Page

Total 0

Steven C Gilman Mailing Address

Above is the net worth, insider trading, and ownership report for Steven C Gilman. You might contact Steven C Gilman via mailing address: 110 Hartwell Avenue, Lexington Ma 02421.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF ADV Part 2A ADV Part 2B ADV Part 3 Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.